CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry

Andrea Igoren Guaricci; Pier Giorgio Masci; Giuseppe Muscogiuri; Marco Guglielmo; Andrea Baggiano; Laura Fusini; Valentina Lorenzoni; Chiara Martini; Daniele Andreini; Anna Giulia Pavon; Giovanni D. Aquaro; Andrea Barison; Giancarlo Todiere; Mark G. Rabbat; Emily Tat; Claudia Raineri; Adele Valentini; Akos Varga-Szemes; U. Joseph Schoepf; Carlo N. De Cecco; Jan Bogaert; Monica Dobrovie; Rolf Symons; Marta Focardi; Annalaura Gismondi; Jordi Lozano-Torres; Josè F. Rodriguez-Palomares; Chiara Lanzillo; Mauro Di Roma; Claudio Moro; Gabriella Di Giovine; Davide Margonato; Manuel De Lazzari; Martina Perazzolo Marra; Alberto Nese; Grazia Casavecchia; Matteo Gravina; Francesca Marzo; Samuela Carigi; Silvia Pica; Massimo Lombardi; Stefano Censi; Angelo Squeri; Alessandro Palumbo; Nicola Gaibazzi; Giovanni Camastra; Stefano Sbarbati; Patrizia Pedrotti; Ambra Masi; Nazario Carrabba

doi:10.1093/europace/euaa401

CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry

Andrea Igoren Guaricci, Pier Giorgio Masci, Giuseppe Muscogiuri, Marco Guglielmo, Andrea Baggiano, Laura Fusini, Valentina Lorenzoni, Chiara Martini, Daniele Andreini, Anna Giulia Pavon, Giovanni D. Aquaro, Andrea Barison, Giancarlo Todiere, Mark G. Rabbat, Emily Tat, Claudia Raineri, Adele Valentini, Akos Varga-Szemes, U. Joseph Schoepf, Carlo N. De CeccoJan Bogaert, Monica Dobrovie, Rolf Symons, Marta Focardi, Annalaura Gismondi, Jordi Lozano-Torres, Josè F. Rodriguez-Palomares, Chiara Lanzillo, Mauro Di Roma, Claudio Moro, Gabriella Di Giovine, Davide Margonato, Manuel De Lazzari, Martina Perazzolo Marra, Alberto Nese, Grazia Casavecchia, Matteo Gravina, Francesca Marzo, Samuela Carigi, Silvia Pica, Massimo Lombardi, Stefano Censi, Angelo Squeri, Alessandro Palumbo, Nicola Gaibazzi, Giovanni Camastra, Stefano Sbarbati, Patrizia Pedrotti, Ambra Masi, Nazario Carrabba

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

50 Cites (Scopus)

Resum

Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.

Idioma original	Anglès
Pàgines (de-a)	1072-1083
Nombre de pàgines	12
Revista	Europace
Volum	23
Número	7
DOIs	https://doi.org/10.1093/europace/euaa401
Estat de la publicació	Publicada - 1 de jul. 2021

Accés al document

10.1093/europace/euaa401

Altres arxius i enllaços

Link to publication in Scopus

Dataset related to the article "CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry"
Guaricci, A. I. (Creador), Masci, P. G. (Col·laborador), Muscogiuri, G. (Col·laborador), Guglielmo, M. (Col·laborador), Baggiano, A. (Col·laborador), Fusini, L. (Col·laborador), Lorenzoni, V. (Col·laborador), Martini, C. (Col·laborador), Andreini, D. (Col·laborador), Pavon, A. G. (Col·laborador), Barison, A. (Col·laborador), Todiere, G. (Col·laborador), Rabbat, M. G. (Col·laborador), Tat, E. (Col·laborador), Raineri, C. (Col·laborador), Valentini, A. (Col·laborador), Varga-Szemes, A. (Col·laborador), Schoepf, U. J. (Col·laborador), De Cecco, C. N. (Col·laborador), Bogaert, J. (Col·laborador), Dobrovie, M. (Col·laborador), Symons, R. (Col·laborador), Focardi, M. (Col·laborador), Gismondi, A. (Col·laborador), Lozano-Torres, J. (Col·laborador), Rodriguez-Palomares, J. F. (Col·laborador), Lanzillo, C. (Col·laborador), Di Roma, M. (Col·laborador), Moro, C. (Col·laborador), Di Giovine, G. (Col·laborador), Margonato, D. (Col·laborador), De Lazzari, M. (Col·laborador), Perazzolo Marra, M. (Col·laborador), Nese, A. (Col·laborador), Casavecchia, G. (Col·laborador), Gravina, M. (Col·laborador), Marzo, F. (Col·laborador), Carigi, S. (Col·laborador), Pica, S. (Col·laborador), Lombardi, M. (Col·laborador), Censi, S. (Col·laborador), Squeri, A. (Col·laborador), Palumbo, A. (Col·laborador), Gaibazzi, N. (Col·laborador), Camastra, G. (Col·laborador), Sbarbati, S. (Col·laborador), Pedrotti, P. (Col·laborador), Masi, A. (Col·laborador), Carrabba, N. (Col·laborador), Pradella, S. (Col·laborador), Timpani, M. (Col·laborador), Cicala, G. (Col·laborador), Presicci, C. (Col·laborador), Puglisi, S. (Col·laborador), Sverzellati, N. (Col·laborador), Santobuono, V. E. (Col·laborador), Pepi, M. (Col·laborador), Schwitter, J. (Col·laborador) & Pontone, G. (Col·laborador), Zenodo, 27 de gen. 2022
DOI: 10.5281/zenodo.5911669, https://zenodo.org/record/5911669
Conjunt de dades

Com citar-ho

Guaricci, A. I., Masci, P. G., Muscogiuri, G., Guglielmo, M., Baggiano, A., Fusini, L., Lorenzoni, V., Martini, C., Andreini, D., Pavon, A. G., Aquaro, G. D., Barison, A., Todiere, G., Rabbat, M. G., Tat, E., Raineri, C., Valentini, A., Varga-Szemes, A., Schoepf, U. J., ... Carrabba, N. (2021). CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry. Europace, 23(7), 1072-1083. https://doi.org/10.1093/europace/euaa401

@article{8e37d5a1b38c4b9c8e0d97e56e48d5b7,

title = "CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry",

abstract = "Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.",

keywords = "Cardiac magnetic resonance, Heart failure, Implantable cardioverter-defibrillator, Non-ischaemic dilated cardiomyopathy, Primary prevention",

author = "Guaricci, {Andrea Igoren} and Masci, {Pier Giorgio} and Giuseppe Muscogiuri and Marco Guglielmo and Andrea Baggiano and Laura Fusini and Valentina Lorenzoni and Chiara Martini and Daniele Andreini and Pavon, {Anna Giulia} and Aquaro, {Giovanni D.} and Andrea Barison and Giancarlo Todiere and Rabbat, {Mark G.} and Emily Tat and Claudia Raineri and Adele Valentini and Akos Varga-Szemes and Schoepf, {U. Joseph} and {De Cecco}, {Carlo N.} and Jan Bogaert and Monica Dobrovie and Rolf Symons and Marta Focardi and Annalaura Gismondi and Jordi Lozano-Torres and Rodriguez-Palomares, {Jos{\`e} F.} and Chiara Lanzillo and {Di Roma}, Mauro and Claudio Moro and {Di Giovine}, Gabriella and Davide Margonato and {De Lazzari}, Manuel and {Perazzolo Marra}, Martina and Alberto Nese and Grazia Casavecchia and Matteo Gravina and Francesca Marzo and Samuela Carigi and Silvia Pica and Massimo Lombardi and Stefano Censi and Angelo Squeri and Alessandro Palumbo and Nicola Gaibazzi and Giovanni Camastra and Stefano Sbarbati and Patrizia Pedrotti and Ambra Masi and Nazario Carrabba",

year = "2021",

month = jul,

day = "1",

doi = "10.1093/europace/euaa401",

language = "English",

volume = "23",

pages = "1072--1083",

journal = "Europace",

issn = "1099-5129",

number = "7",

}

Guaricci, AI, Masci, PG, Muscogiuri, G, Guglielmo, M, Baggiano, A, Fusini, L, Lorenzoni, V, Martini, C, Andreini, D, Pavon, AG, Aquaro, GD, Barison, A, Todiere, G, Rabbat, MG, Tat, E, Raineri, C, Valentini, A, Varga-Szemes, A, Schoepf, UJ, De Cecco, CN, Bogaert, J, Dobrovie, M, Symons, R, Focardi, M, Gismondi, A, Lozano-Torres, J, Rodriguez-Palomares, JF, Lanzillo, C, Di Roma, M, Moro, C, Di Giovine, G, Margonato, D, De Lazzari, M, Perazzolo Marra, M, Nese, A, Casavecchia, G, Gravina, M, Marzo, F, Carigi, S, Pica, S, Lombardi, M, Censi, S, Squeri, A, Palumbo, A, Gaibazzi, N, Camastra, G, Sbarbati, S, Pedrotti, P, Masi, A & Carrabba, N 2021, 'CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry', Europace, vol. 23, núm. 7, pàg. 1072-1083. https://doi.org/10.1093/europace/euaa401

CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry. / Guaricci, Andrea Igoren; Masci, Pier Giorgio; Muscogiuri, Giuseppe et al.
In: Europace, Vol. 23, Núm. 7, 01.07.2021, pàg. 1072-1083.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy

T2 - An international Registry

AU - Guaricci, Andrea Igoren

AU - Masci, Pier Giorgio

AU - Muscogiuri, Giuseppe

AU - Guglielmo, Marco

AU - Baggiano, Andrea

AU - Fusini, Laura

AU - Lorenzoni, Valentina

AU - Martini, Chiara

AU - Andreini, Daniele

AU - Pavon, Anna Giulia

AU - Aquaro, Giovanni D.

AU - Barison, Andrea

AU - Todiere, Giancarlo

AU - Rabbat, Mark G.

AU - Tat, Emily

AU - Raineri, Claudia

AU - Valentini, Adele

AU - Varga-Szemes, Akos

AU - Schoepf, U. Joseph

AU - De Cecco, Carlo N.

AU - Bogaert, Jan

AU - Dobrovie, Monica

AU - Symons, Rolf

AU - Focardi, Marta

AU - Gismondi, Annalaura

AU - Lozano-Torres, Jordi

AU - Rodriguez-Palomares, Josè F.

AU - Lanzillo, Chiara

AU - Di Roma, Mauro

AU - Moro, Claudio

AU - Di Giovine, Gabriella

AU - Margonato, Davide

AU - De Lazzari, Manuel

AU - Perazzolo Marra, Martina

AU - Nese, Alberto

AU - Casavecchia, Grazia

AU - Gravina, Matteo

AU - Marzo, Francesca

AU - Carigi, Samuela

AU - Pica, Silvia

AU - Lombardi, Massimo

AU - Censi, Stefano

AU - Squeri, Angelo

AU - Palumbo, Alessandro

AU - Gaibazzi, Nicola

AU - Camastra, Giovanni

AU - Sbarbati, Stefano

AU - Pedrotti, Patrizia

AU - Masi, Ambra

AU - Carrabba, Nazario

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.

AB - Aims: The aim of this registry was to evaluate the additional prognostic value of a composite cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) evaluation in a large cohort of consecutive unselected non-ischaemic cardiomyopathy (NICM) patients. Methods and results: In the DERIVATE registry (www.clinicaltrials.gov/registration: RCT#NCT03352648), 1000 (derivation cohort) and 508 (validation cohort) NICM patients with chronic heart failure (HF) and left ventricular ejection fraction <50% were included. All-cause mortality and major adverse arrhythmic cardiac events (MAACE) were the primary and secondary endpoints, respectively. During a median follow-up of 959 days, all-cause mortality and MAACE occurred in 72 (7%) and 93 (9%) patients, respectively. Age and >3 segments with midwall fibrosis on late gadolinium enhancement (LGE) were the only independent predictors of all-cause mortality (HR: 1.036, 95% CI: 1.0117-1.056, P < 0.001 and HR: 2.077, 95% CI: 1.211-3.562, P = 0.008, respectively). For MAACE, the independent predictors were male gender, left ventricular end-diastolic volume index by CMR (CMR-LVEDVi), and >3 segments with midwall fibrosis on LGE (HR: 2.131, 95% CI: 1.231-3.690, P = 0.007; HR: 3.161, 95% CI: 1.750-5.709, P < 0.001; and HR: 1.693, 95% CI: 1.084-2.644, P = 0.021, respectively). A composite clinical and CMR-based risk score provided a net reclassification improvement of 63.7% (P < 0.001) for MAACE occurrence when added to the model based on SOC evaluation. These findings were confirmed in the validation cohort. Conclusion: In a large multicentre, multivendor cohort registry reflecting daily clinical practice in NICM work-up, a composite clinical and CMR-based risk score provides incremental prognostic value beyond SOC evaluation, which may have impact on the indication of implantable cardioverter-defibrillator implantation.

KW - Cardiac magnetic resonance

KW - Heart failure

KW - Implantable cardioverter-defibrillator

KW - Non-ischaemic dilated cardiomyopathy

KW - Primary prevention

UR - http://www.scopus.com/inward/record.url?scp=85112125923&partnerID=8YFLogxK

U2 - 10.1093/europace/euaa401

DO - 10.1093/europace/euaa401

M3 - Article

C2 - 33792661

AN - SCOPUS:85112125923

SN - 1099-5129

VL - 23

SP - 1072

EP - 1083

JO - Europace

JF - Europace

IS - 7

ER -

CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: An international Registry

Resum

Accés al document

Altres arxius i enllaços

Fingerprint

Conjunts de dades

Dataset related to the article "CarDiac magnEtic Resonance for prophylactic Implantable-cardioVerter defibrillAtor ThErapy in Non-Ischaemic dilated CardioMyopathy: an international Registry"

Com citar-ho